3Gregory RK,Powles TJ,Salter J,et al.Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients ina randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy[J].Breast Cancer Res Treat,2000,59(2):171-175.
2[1]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy of local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 1997, 15: 2483.
3[2]Hortobagyi GN. Drug therapy: treatment of breast can cer. N Engl J Med, 1998, 339: 974.
4[3]Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res, 1992, 52: 2371.
5[4]Bonadonna G. Evolving concepts in systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52: 2127.
6[5]Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusionalchemotherapy for large early breast cancer. J Clin Oncol, 1995, 13: 424.
7[6]Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomized trials: S6. Eur J Cancer, 1994, 30A: 645.
8[7]Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl CancerInst, 1990, 82: 1539.
9[8]Shao ZM, Li J, Wu J, et al. Primary chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat, 1999, 1288: 1.
10[9]Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol, 1995, 13: 547.
2Osako T,Horii R,Matsuura M.Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy [J],J Cancer Res Clin Oncol,2010,136(2):784-785.
